- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 -

- Solid received a positive opinion from the European Medicines Agency (EMA) on its Pediatric Investigation Plan (PIP) for SGT-003, establishing alignment on a pediatric clinical development framework in Europe -

- 46 participants have been dosed with SGT-003 in the Phase 1/2 INSPIRE DUCHENNE clinical trial using a steroid-only prophylactic immunomodulation regimen; SGT-003 has been generally well tolerated as of a May 4, 2026, cutoff date -